Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10301313 Polymorphs

Patent 10301313 was granted and assigned to Boehringer Ingelheim on May, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Boehringer Ingelheim

Current Assignee

Boehringer Ingelheim

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

May 28, 2019

Patent Application Number

15725426

Date Filed

October 5, 2017

Patent Citations

US Patent 10023574 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Patent Citations Received

US Patent 11919903 Polymorphs

0

US Patent 11291668 Uses of DPP IV inhibitors

US Patent 11911388 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

0

US Patent 11911387 Vasoprotective and cardioprotective antidiabetic therapy

0

US Patent 10668074 Uses of DPP IV inhibitors

US Patent 10973827 DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

US Patent 11033552 DPP IV inhibitor formulations

Patent Primary Examiner

Noble E Jarrell

Patent abstract

The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10301313 Polymorphs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool